Post Content

Before drug manufacturers ship vaccines to distributors they, along with the Food and Drug Administration (FDA), always test them to determine that they meet all safety and efficacy standards. As part of its quality assurance program, manufacturer Sanofi Pasteur, performs additional routine, ongoing tests of their flu vaccines to ensure that they continue to meet required specifications after they have been distributed health care providers.

This week, after performing these tests, Sanofi Pasteur notified Centers for Disease Control (CDC) and the FDA that the antigen content in a batch (known as a "lot") of syringes intended for children 6 months through 35 months of age distributed to providers in November, had dropped below a pre-specified limit making them slightly less potent.

Consequently, Sanofi Pasteur tested additional lots and found that three others also had an antigen content that had fallen below pre-specified limits. This means that doses from these four vaccine lots no longer meet the specifications for antigen content. Therefore, Sanofi is conducting a voluntary recall of these affected lots and has asked providers to return any vaccine they may have from these lots to the manufacturer.

The affected vaccine met all specifications at the time of release and both CDC and FDA have determined that there are no safety concerns for children who received this vaccine. Parents of children who received vaccines from the recalled lots do not need to take any action other than make sure their child receives their second dose if they have not already. There is NO need to revaccinate children who have received vaccine from these lots. The antigen content in the affected lots of vaccine is only slightly below the specification limit and experts expect it to still be effective against the H1N1 flu.

This drop in antigen content below the required specification only occurred in Sanofi Pasteur’s pediatric H1N1 monovalent vaccine in 0.25 mL pre-filled syringes. The same vaccine packaged in other forms, such as pre-filled syringes for older children and adults and multi-dose vials, continue to meet specifications.

For additional information please see CDC’s Questions and Answers related to the withdrawn vaccine at http://www.cdc.gov/h1n1flu/vaccination/syringes_qa.htm

We encourage all residents to utilize the comments section on this blog to engage with us and each other. While we cannot respond to every comment or question directly, we find them very helpful to understand your questions and concerns and plan for future posts.

Written By:


Communications Office

Recent Posts

DPH Kicks Off Town Hall Meetings to Address Underage Drinking and Prescription Drug Abuse posted on Apr 15

DPH Kicks Off Town Hall Meetings to Address Underage Drinking and Prescription Drug Abuse

Last week, the Department hosted the first in a series of statewide Town Hall Meetings that will examine what can be done to prevent underage drinking and prescription drug abuse in the Commonwealth.  Bureau of Substance Abuse Services (BSAS) Director Hilary Jacobs was joined at the   …Continue Reading DPH Kicks Off Town Hall Meetings to Address Underage Drinking and Prescription Drug Abuse

A Healthier Commute – for a Healthier Community posted on Apr 14

A Healthier Commute – for a Healthier Community

When it comes to our daily commute, we could all use a little inspiration. That’s why I want to take this opportunity to encourage employers in eastern Massachusetts to participate in the 2014 Walk/Ride Corporate Challenge — an annual competition that encourages workers to use   …Continue Reading A Healthier Commute – for a Healthier Community

Highlights of the April 9th Public Health Council Meeting posted on Apr 9

This month’s meeting of the Public Health Council included a series of Determination of Need (DON) requests, followed by a set of three of informational presentations on pending amendments to regulations. The Council took up deliberations for a series of three Determination of Need requests,   …Continue Reading Highlights of the April 9th Public Health Council Meeting